These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 8368752

  • 1. Transfection of TGF-beta producing tumors with IL-2 elicits tumor rejection.
    Lord E, McAdam A, Felcher A, Woods M, Pulaski B, Hutter E, Frelinger J.
    Ann N Y Acad Sci; 1993 Aug 12; 690():346-8. PubMed ID: 8368752
    [No Abstract] [Full Text] [Related]

  • 2. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA.
    J Exp Med; 2003 Dec 01; 198(11):1741-52. PubMed ID: 14657224
    [Abstract] [Full Text] [Related]

  • 3. A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-beta prolongs the survival of tumor-bearing rats.
    Yamamoto Y, Ueda Y, Itoh T, Iwamoto A, Yamagishi H, Shimagaki M, Teramoto K.
    Oncol Rep; 2006 Dec 01; 16(6):1277-84. PubMed ID: 17089050
    [Abstract] [Full Text] [Related]

  • 4. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine.
    Hsieh CL, Chen DS, Hwang LH.
    Hum Gene Ther; 2000 Mar 20; 11(5):681-92. PubMed ID: 10757348
    [Abstract] [Full Text] [Related]

  • 5. Coexpression of IL-2 and gamma-IFN enhances tumor immunity.
    McAdam A, Pulaski B, Harkins S, Hutter E, Frelinger J, Lord E.
    Ann N Y Acad Sci; 1993 Aug 12; 690():349-51. PubMed ID: 8368753
    [No Abstract] [Full Text] [Related]

  • 6. Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response.
    Gunji Y, Tagawa M, Matsubara H, Takenaga K, Shimada H, Kondo F, Suzuki T, Nakajima K, Aoki T, Asano T, Ochiai T, Isono K, Kageyama H, Nakamura Y, Sakiyama S.
    Int J Cancer; 1996 Mar 28; 66(1):135-9. PubMed ID: 8608957
    [Abstract] [Full Text] [Related]

  • 7. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
    Clin Cancer Res; 2005 Jun 15; 11(12):4512-20. PubMed ID: 15958637
    [Abstract] [Full Text] [Related]

  • 8. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
    Li XF, Takiuchi H, Zou JP, Katagiri T, Yamamoto N, Nagata T, Ono S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1993 Mar 15; 84(3):315-25. PubMed ID: 8098027
    [Abstract] [Full Text] [Related]

  • 9. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth.
    Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K.
    Biochim Biophys Acta; 1992 Oct 27; 1137(2):189-96. PubMed ID: 1384712
    [Abstract] [Full Text] [Related]

  • 10. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
    Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE.
    Proc Natl Acad Sci U S A; 1996 Apr 02; 93(7):2909-14. PubMed ID: 8610141
    [Abstract] [Full Text] [Related]

  • 11. Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice.
    Meijssen MA, Brandwein SL, Reinecker HC, Bhan AK, Podolsky DK.
    Am J Physiol; 1998 Mar 02; 274(3):G472-9. PubMed ID: 9530147
    [Abstract] [Full Text] [Related]

  • 12. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM.
    Cancer Lett; 2008 Dec 18; 272(2):285-95. PubMed ID: 18760876
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
    Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T.
    Proc Natl Acad Sci U S A; 1993 Apr 01; 90(7):2774-8. PubMed ID: 8464888
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
    Marshall NA, Galvin KC, Corcoran AM, Boon L, Higgs R, Mills KH.
    Cancer Res; 2012 Feb 01; 72(3):581-91. PubMed ID: 22158905
    [Abstract] [Full Text] [Related]

  • 15. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes.
    Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM.
    J Leukoc Biol; 1999 Dec 01; 66(6):981-8. PubMed ID: 10614781
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-2 suppresses activated macrophage intracellular killing activity by inducing macrophages to secrete TGF-beta.
    Nelson BJ, Danielpour D, Rossio JL, Turpin J, Nacy CA.
    J Leukoc Biol; 1994 Jan 01; 55(1):81-90. PubMed ID: 8283143
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice.
    Lúdvíksson BR, Ehrhardt RO, Strober W.
    J Immunol; 1997 Oct 01; 159(7):3622-8. PubMed ID: 9317162
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.